What is the current size and annual growth rate of the anaphylaxis market?
The anaphylaxis market size has grown strongly in recent years. It will grow from $3.24 billion in 2024 to $3.51 billion in 2025 at a compound annual growth rate (CAGR) of 8.4%. The growth in the historic period can be attributed to the rising prevalence of food allergies, increased awareness of anaphylaxis, growing healthcare infrastructure, better diagnosis and management, and increasing availability of epinephrine auto-injectors.
The anaphylaxis market size is expected to see strong growth in the next few years. It will grow to $4.81 billion in 2029 at a compound annual growth rate (CAGR) of 8.2%. The growth in the forecast period can be attributed to increasing urbanization and lifestyle changes, a growing incidence of anaphylaxis cases, rising disposable incomes in emerging markets, government funding for allergy research, and innovations in delivery systems for emergency treatment. Major trends in the forecast period include growing demand for injectable auto-injectors, integration of digital health solutions in anaphylaxis management, increased focus on product affordability, rise in preventative treatments and vaccines, increased use of biologics for allergy treatment.
Get Your Free Sample of The Global Anaphylaxis Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21096&type=smp
Which major factors have contributed to the expansion of the anaphylaxis market?
The rising prevalence of food allergies is expected to propel the growth of the anaphylaxis market going forward. Food allergies are immune system reactions triggered by certain foods, causing symptoms that range from mild to severe, including life-threatening anaphylaxis. The rising prevalence of food allergies are due to factors such as changing dietary habits, environmental influences, and improved awareness and diagnosis. Anaphylaxis treatment provides critical, life-saving intervention for food allergy patients by rapidly reversing severe allergic reactions, reducing symptoms such as swelling, difficulty breathing, and drop in blood pressure, ensuring immediate stabilization and preventing potentially fatal outcomes, while empowering patients with the tools for timely action in future allergic incidents. For instance, in September 2024, according to the World Health Organization (WHO), a Switzerland-based United Nations (UN) organization, around 220 million people globally are affected by food allergies. A single food product can include multiple allergens, and individuals may be allergic to more than one type of food. Additionally, in May 2024, according to the Patterns and Prevalence of Adult Food Allergy (PAFA) report published by the Food Standards Agency (FSA), a UK-based non-ministerial department, over 30% of adults reported food-related adverse reactions, and clinical assessments confirmed food allergies in approximately 6% of UK adults, equating to around 2.4 million people. Therefore, the rising prevalence of food allergies is driving the growth of the anaphylaxis market.
How is the anaphylaxis market segmented?
The anaphylaxis market covered in this report is segmented –
1) By Drug Class: Epinephrine, Steroids, Antihistamines, Beta-antagonists, Other Drug Class
2) By Route Of Administration: Parenteral, Oral, Other Routes Of Administration
3) By Application: Food Allergy, Pollen Allergy, Dust Mites Allergy, Other Applications
Subsegments:
1) By Epinephrine: Auto-injectors, Prefilled Syringes, Vials
2) By Steroids: Corticosteroids, Glucocorticoids, Mineralocorticoids
3) By Antihistamines: H1-receptor Antagonists, H2-receptor Antagonists
4) By Beta-antagonists: Selective Beta-blockers, Non-selective Beta-blockers
5) By Other Drug Class: Leukotriene Receptor Antagonists, Mast Cell Stabilizers
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/anaphylaxis-global-market-report
Who are the top competitors in the anaphylaxis market?
Major companies operating in the anaphylaxis market are Pfizer Inc., Johnson & Johnson Services Inc., Merck & Co. Inc., Bayer AG, Novartis AG, Sanofi SA, AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline Plc, F. Hoffman-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Bausch Health Companies Inc., Perrigo Company plc, Dr Reddy’s Laboratories Ltd., Cipla Ltd., Amneal Pharmaceuticals Inc., Mylan N.V., ALK-Abelló, Stallergenes Greer, Allergy Therapeutics
Which key trends are expected to influence the anaphylaxis market in the coming years?
Major companies operating in the anaphylaxis market are focusing on developing advanced epinephrine nasal spray, which enable faster, more efficient drug delivery during emergencies. Epinephrine nasal spray is a medical device that delivers epinephrine (adrenaline) through the nasal passages as a treatment for severe allergic reactions, including anaphylaxis. For instance, in August 2024, ARS Pharmaceuticals, a US-based biotechnology company, announced Neffy (epinephrine nasal spray) approved by the Food and Drug Administration, a US-based government agency, marking it as the first and only needle-free treatment for type I allergic reactions, including anaphylaxis. This innovative nasal spray provides a non-invasive alternative to traditional epinephrine autoinjectors, offering a potentially more accessible option for emergency treatment. Neffy aims to improve patient compliance by eliminating the need for needles while delivering rapid, life-saving epinephrine during severe allergic reactions.
Which regional trends are influencing the anaphylaxis market, and which area dominates the industry?
North America was the largest region in the anaphylaxis market in 2024. The regions covered in the anaphylaxis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Anaphylaxis Market Report 2025 Offer?
The anaphylaxis market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Anaphylaxis is a severe, life-threatening allergic reaction that occurs rapidly, often resulting in difficulty breathing, swelling, and a drop in blood pressure, requiring immediate medical intervention. Management of anaphylaxis involves prompt administration of epinephrine, followed by monitoring in a healthcare setting to stabilize the patient and prevent further complications.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21096
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
